Images List Premium Download Classic

Anxiety

Anxiety-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Antagonists of the kappa opioid receptor
University Of Kansas
September 14, 2017 - N°20170260141

The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (kor) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.
Method of enhancing a participant's performance in a sporting activity
University Of Kansas
September 14, 2017 - N°20170259149

According to one aspect of the present invention, a method of improving a participant's ability to move an object toward a desired target through athletic movement is provided. The method comprises establishing a point of focus that is positioned outward from a participant's body. The method further comprises instructing the participant to continuously move the point of focus through one ...
Disease susceptibility
Leiden University
August 24, 2017 - N°20170240967

The invention provides a method of assessing the susceptibility of a subject to, or aiding the diagnosis of, an anxiety disorder or depression, the method comprising determining whether the subject has a haplotype comprising rs3216799, rs6814934, rs7658048, rs2070950 and rs2070951 with respective alleles ‘+ct, ‘c’, ‘t’, ‘c’ and ‘c’. The invention ...
Anxiety Patent Pack
Download + patent application PDFs
Anxiety Patent Applications
Download + Anxiety-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Anxiety-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Nutritional supplement for use in combatting stress and anxiety in pets
Domes Pharma
July 27, 2017 - N°20170209547

Nutritional supplement for veterinary, for use in combatting stress and anxiety in pets, characterized in that it contains a mixture of α-lactalbumin and magnesium.
Novel anxiolytic compounds
Domes Pharma
June 29, 2017 - N°20170183347

Which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Merck Patentgesellschaft
June 29, 2017 - N°20170182037

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid ...
Anxiety Patent Pack
Download + patent application PDFs
Anxiety Patent Applications
Download + Anxiety-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Anxiety-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Neuroplasticity games for depression
University Of South Florida
May 25, 2017 - N°20170148343

A training program is configured to systematically drive neurological changes to treat depression, mood and anxiety disorders. The training program includes an inference renormalization game that presents three subsets of stimuli and prompts a game participant to selectively respond or withhold responding to one or two of the stimulus subsets.
Compositions and methods for the treatment of neurological diseases
University Of South Florida
May 11, 2017 - N°20170129870

The compositions and compounds of formula i which includes a salt of duloxetine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder, ...
System and method for enabling a user to overcome social anxiety
Dharma Life Sciences Llc
May 04, 2017 - N°20170124905

A system is provided for enabling a user to overcome social anxiety. The system is configured to enable the user to engage in a first and a second activity in a virtual environment, directed to rewire a first and a second defective wiring, respectively. The first defective wiring results in an individual give priority to threatening information in social environments. ...
Magnesium compositions and uses thereof for neurological disorders
Neurocentria, Inc.
April 27, 2017 - N°20170112875

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another ...
Magnesium compositions and uses thereof for neurological disorders
Neurocentria, Inc.
April 20, 2017 - N°20170106016

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another ...
Indolin-2-one or pyrrolo-pyridin-2-one derivatives
Neurocentria, Inc.
April 13, 2017 - N°20170101409

The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory ...
Methods of diagnosing and treating anxiety disorder
The Children's Hospital Of Philadelphia
March 30, 2017 - N°20170087141

Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mglur) network genes and wherein treatment is with nonspecific activators of mglurs such as fasoracetam.
Anxiety Patent Pack
Download + patent application PDFs
Anxiety Patent Applications
Download + Anxiety-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Anxiety-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Peptides as oxytocin agonists
Hoffmann-la Roche Inc.
March 23, 2017 - N°20170081368

The present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post-traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.
Heteroaromatic compounds and their use as dopamine d1 ligands
Hoffmann-la Roche Inc.
March 02, 2017 - N°20170057947

And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e. G., schizophrenia (e. G., its cognitive and negative symptoms), cognitive impairment (e. G., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, ...
(2r)-2-propyloctanoic acid for functional brain disease
Ono Pharmaceutical Co., Ltd.
February 23, 2017 - N°20170049737

An agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the functional brain disease includes (2r)-2-propyloctanoic acid or a salt thereof. The agent may be safely administered to patients of, for example, functional brain diseases such as depression, menopausal mood disorder, perimenopausal mood disorder, panic disorder, irritable bowel syndrome, social anxiety disorder, ...
Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium ...
The Johns Hopkins University
February 02, 2017 - N°20170029382

The present invention provides compounds of formula i which are capable of inhibition of the activation of hnav1. 1 or hnav1. 6 sodium channels in neurons. Pharmaceutical compositions comprising these compounds are also provided. Methods for prevention and treatment of neurological disorders, including, for example, seizures and seizure disorders, including lennox-gastaut syndrome, dravet syndrome, epileptic encephalopathies, autism, familial hemiplegic migraine (fhm), anxiety ...
Methods for the treatment of depression and anxiety
The Arizona Board Of Regents On Behalf Of The University Of Arizona
January 26, 2017 - N°20170020953

Methods of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising ac-nle4-c[asp5-his6-(nme)d-nal(2′)7-arg8-trp9-(nme)lys10]-nh2 (peptide 9), in a pharmaceutically acceptable carrier is administered to the subject. Peptide 9 is a selective mc5r antagonist, ...
Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
The Arizona Board Of Regents On Behalf Of The University Of Arizona
January 19, 2017 - N°20170014493

Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating ptsd. The ...
Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use
University Of South Florida
January 05, 2017 - N°20170000785

The subject invention concerns materials and methods for treating depression, stress disorders, such as ptsd, anxiety disorders, and/or a neurodegenerative disease or condition in a person or animal. In one embodiment, a person or animal in need of treatment is administered one or more compounds or drugs, or a composition comprising the one or more compounds or drugs, that ...
Long range portable pet or owner initiated two way audio-video communication device
University Of South Florida
December 22, 2016 - N°20160366859

A portable device and a method for a domestic pet to contact its master whenever the pet desires so is disclosed. The device comprises of two units and an interconnecting mechanism between them via wireless communication methods such as bluetooth© or other equivalent rf technologies. The first unit comprises of a circuit board, an antenna, a camera, lcd screen, ...
Loading